osteoporosis%20in%20women
OSTEOPOROSIS IN WOMEN
Osteoporosis is a progressive, systemic, skeletal disease characterized by decreased bone mass and microarchitectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history of fracture, advanced age, comorbidities, etc) that are present, the greater the risk of fracture.

Monitoring

Aim of monitoring is to increase adherence to therapy and to verify response to therapy

Bone Mineral Density (BMD) Measurement

  • Recommended every 1-2 years after initiation of therapy until stable findings and every 2 years thereafter depending on the clinical outcome
  • Central dual energy X-ray absorptiometry (DXA) of the spine or hip is the gold standard for serial BMD assessment
    • Should be done every 2 years
    • If spine, hip or both cannot be assessed, 33% radius site can be used 
  • Patient follow-up ideally should be done within the same facility using the same machine 
  • Age-, disease- and treatment-related BMD changes can be monitored using quantitative computed tomography (QCT) measurement of trabecular BMD 

Bone Turnover Markers

  • Bone resorption markers may be measured before starting therapy and 3 or 6 months after starting treatment
  • Bone formation markers may be measured before starting therapy and 6 months later
  • High levels of bone resorption markers are associated with an increased risk of osteoporotic fractures
    • Resorption markers may be used for assessing fracture risk in selected patients when BMD and clinical risk factors are not sufficient to make treatment decisions

Vertebral Imaging

  • Repeat vertebral imaging is indicated for patients with the following:
    • Documented height loss
    • Presence of vertebral pain
    • Changes in posture
    • Chest X-ray abnormalities
    • Due for reevaluation of treatment with possible withdrawal of therapy
    • Presence of vertebral fracture during off-treatment interval
Reassessment of Postmenopausal Women on Long-Term Bisphosphonate Therapy 
  • Postmenopausal women who have been taking oral bisphosphonates for >5 years or IV bisphosphonates for >3 years should be reassessed for presence of fractures prior to initiation and during therapy
    • Bisphosphonate therapy can be continued beyond 3-5 years in patients ≥75 years old, on high-dose oral glucocorticoid treatment, with prior history of hip or vertebral fracture, or who sustained a low-trauma fracture during therapy
  • If fractures occurred, treatment with bisphosphonates may be continued or may consider the use of other agents
  • If fracture-free, assess BMD T-score or fracture risk
    • If with hip BMD T-score of <-2.5 or with high fracture risk, consider continuing bisphosphonate therapy or may change into other alternative agents
    • If with normal bone mass and still no fractures, may consider withholding treatment and advise patient to follow up for fracture risk assessment every 1.5-3 years

Specialist Referral

  • Consider a referral to a specialist when: 
    • Fragility fractures are experienced
    • A non-major trauma fracture is sustained by a patient with normal BMD 
    • Continued bone loss or recurrent fractures happens in a patient on therapy but has no clear causes of bone loss that are treatable
    • Osteoporosis has uncommon features, is severe, or rare secondary conditions are present, eg hyperparathyroidism, increased prolactin
    • A condition is present that makes management difficult, eg chronic kidney disease, malabsorption
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
27 Nov 2017
Transdermal oestradiol added to progesterone reduces menopause-related depression, researchers reported at the annual meeting of The North American Menopause Society in Philadelphia, US.
6 days ago
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.
Shilpa Kolhe, MBBS, MD, MRCOG; Shilpa Deb, MBBS, DGO, MRCOG, 01 Aug 2012

Dysmenorrhoea is a medical condition characterized by severe uterine pain during menstruation manifesting as cyclical lower abdominal or pelvic pain, which may also radiate to the back and thighs. The term dysmenorrhoea is derived from the Greek words ‘dys’ meaning difficult, painful or abnormal, ‘meno’ meaning month, and ‘rrhea’ meaning flow. It is commonly divided into primary dysmenorrhoea, where there is no coexistent pathology, and secondary dysmenorrhoea where there is an identifiable pathological condition known to contribute to painful menstruation. Symptoms of primary dysmenorrhoea begin a few hours before the start of menstruation and are often relieved during the first few days of bleeding. The initial onset of primary dysmenorrhoea is usually shortly after menarche (6–12 months), when ovulatory cycles are established. Secondary dysmenorrhoea can also occur at any time after menarche but is most commonly observed in women in their third and fourth decade of life in association with an existing condition.

27 Nov 2017
Chronic hepatitis B virus (HBV) infection is a global problem. Chronic HBV infection is probably the most common maternal infection encountered in Hong Kong, China, and Southeast Asia. In Hong Kong, which is one of the endemic areas, immunisation against HBV was first provided in 1983 to infants born to mothers who were screened positive for hepatitis B surface antigen (HBsAg). Immunisation became widespread since November 1988, but HBsAg-positive mothers are still encountered frequently.1